Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11453608 | 0.74 | TAAR1 (1.00) | TAAR1POLBMAPTTDP1CYP3A4 | |
| SCHEMBL11453607 | 0.74 | TAAR1 (1.00) | TAAR1POLBMAPTTDP1CYP3A4 | |
| SCHEMBL892267 | 0.73 | TAAR1 (0.62) | TAAR1POLBMAPTTDP1CYP3A4 | |
| SCHEMBL250367 | 0.72 | TAAR1 (0.46) | TAAR1POLBMAPTTDP1CYP3A4 | |
| SCHEMBL1533571 | 0.71 | — | — | |
| SCHEMBL4263926 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL29101971 | 0.71 | TAAR1 (0.45) | TAAR1POLBMAPTTDP1CYP3A4 | |
| SCHEMBL2059056 | 0.71 | — | — | |
| SCHEMBL14037460 | 0.71 | — | — | |
| SCHEMBL892031 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118978488-B | Preparation method of 5-aminoimidazole-4-methyl formate | 大连科迈医药科技有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-118978488-A | Preparation method of 5-aminoimidazole-4-methyl formate | 大连科迈医药科技有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-118978488-B | Preparation method of 5-aminoimidazole-4-methyl formate | 大连科迈医药科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-118978488-B | Preparation method of 5-aminoimidazole-4-methyl formate | 大连科迈医药科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-118978488-A | Preparation method of 5-aminoimidazole-4-methyl formate | 大连科迈医药科技有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118978488-A | Preparation method of 5-aminoimidazole-4-methyl formate | 大连科迈医药科技有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | US | disclosed |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-03-21 | — | — | US | disclosed |
| EP-3737684-B1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-11-16 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20200369672-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369672-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | TAAR1 438/4885POLB 4735/4885MAPT 4368/4885 |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | TAAR1 438/4885POLB 4735/4885MAPT 4368/4885 |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | C5AR1, C3AR1, C5AR2 | TAAR1 562/4885POLB 3301/4885MAPT 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.